Building successful life sciences companies.

With over $200 million of committed capital under management, Genesys is one of the largest Canadian-based exclusively focused on the life sciences industry. View our portfolio.

Building companies, accelerating development.

Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life science investment opportunities.

Investor Login

Sign in to our secure investor area to receive personalized updates and information. Login now »

Recent Additions

Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018
Feb. 19, 2019 - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018... Read more
Fusion Pharma Announces First Patient Dosing In A Phase 1 Clinical Trial Of [225Ac]-FPI-1434 Injection In Patients With Advanced Solid Tumors
February 19, 2019 – Today Fusion Pharmaceuticals announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors... Read more